Maria Antonia Bianco
Overview
Explore the profile of Maria Antonia Bianco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tursi A, Piovani D, Brandimarte G, Di Mario F, Elisei W, Picchio M, et al.
Intest Res
. 2024 Aug;
23(1):96-106.
PMID: 39129357
Background/aims: Patients with diverticular disease (DD) frequently have abnormal bowel movements. However, it is unknown whether the entity of these alterations is associated with the severity of DD. We aimed...
2.
Scimia M, Pepe F, Russo G, Palumbo L, Malapelle U, Chuang R, et al.
J Clin Pathol
. 2024 Apr;
77(8):557-560.
PMID: 38649261
Cell-free DNA (cfDNA) has long been established as a useful diagnostic and prognostic tool in a variety of clinical settings, ranging from infectious to cardiovascular and neoplastic diseases. However, non-neoplastic...
3.
Tursi A, Mocci G, Scaldaferri F, Napolitano D, Maresca R, Pugliese D, et al.
Expert Opin Biol Ther
. 2024 Jan;
24(1-2):101-109.
PMID: 38250818
Background: Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist recently approved for treating ulcerative colitis (UC) but with limited real-world data. Therefore, we evaluated the effectiveness and safety of UST in...
4.
Tursi A, Piovani D, Brandimarte G, Di Mario F, Elisei W, Picchio M, et al.
United European Gastroenterol J
. 2023 Aug;
11(7):642-653.
PMID: 37550901
Background And Aims: The Diverticular Inflammation and Complication Assessment (DICA) classification and the Combined Overview on Diverticular Assessment (CODA) were found to be effective in predicting the outcomes of Diverticular...
5.
Tursi A, Piovani D, Brandimarte G, Di Mario F, Elisei W, Picchio M, et al.
Am J Gastroenterol
. 2023 Jun;
118(11):2088-2092.
PMID: 37314163
Introduction: We assessed the prevalence and clinical outcomes of segmental colitis associated with diverticulosis (SCAD) in patients with newly diagnosed diverticulosis. Methods: A 3-year international, multicenter, prospective cohort study was...
6.
Mocci G, Tursi A, Maconi G, Cataletti G, Mantia B, Serio M, et al.
Expert Opin Biol Ther
. 2023 Feb;
23(3):293-304.
PMID: 36843568
Background: Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ. Research...
7.
Scaglione G, Oliviero G, Labianca O, Bianco M, Granata R, Ruggiero L, et al.
Dig Dis
. 2023 Jan;
41(5):708-718.
PMID: 36649696
Background: One-day low-residue diet (LRD) is recommended before colonoscopy, but only three single-center trials compared the 1-day versus 3-day LRD. The aim of this multicenter study was to compare the...
8.
Tursi A, Mocci G, Cuomo A, Ferronato A, Elisei W, Picchio M, et al.
J Gastrointestin Liver Dis
. 2022 Dec;
31(4):411-416.
PMID: 36535057
Background And Aims: Adalimumab (ADA) biosimilars have been included into the therapeutic armamentarium of inflammatory bowel disease (IBD); however, comparative data on the efficacy and safety of the different ADA...
9.
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco M, Colucci R, et al.
Inflamm Bowel Dis
. 2022 May;
29(3):376-383.
PMID: 35579320
Background: Adalimumab (ADA) biosimilars have entered the therapeutic armamentarium of inflammatory bowel disease (IBD), allowing for the treatment of a greater number of patients for their reduced cost than the...
10.
Tursi A, Mocci G, Allegretta L, Aragona G, Bianco M, Colucci R, et al.
Expert Opin Biol Ther
. 2021 Dec;
22(2):313-320.
PMID: 34904510
Background: To compare the performances of Infliximab (IFX) biosimilar CT-P13 and SB2 in the treatment of Inflammatory Bowel Diseases (IBD) outpatients in Italy. Research Design And Methods: Three hundred and...